AZ BMS Diabetes Franchise

[Anonymous]

What are your issues and how would you fix them?

 

[Anonymous]

What are your issues and how would you fix them?

To many reps, but that will all be taken care of next year.

 

[Anonymous]

What are your issues and how would you fix them?

What are your issues & how would you fix them? Moron.

 

[Anonymous]

What are your issues and how would you fix them?

Formulary access, challenging administration, cost, better treatment options!

 

[Anonymous]

What are your issues and how would you fix them?

The issue is BMS is no longer interested in diabetes research. The sales force will eventually be drastically reduced which will eliminate a significant number of jobs. The previous executive management's mantra was BMS/AZ being the diabetes leader.

Dec 13 (Reuters) - Bristol-Myers Squibb and AstraZeneca said they would pull a new diabetes drug from the German market because they had failed to agree on a price with a body of medical insurers.

The decision to stop marketing oral drug dapagliflozin in Germany comes just a day after it was endorsed by an advisory panel to the U.S. Food and Drug Administration.

The two companies said in a joint statement on Friday that the new drug, which had already been launched in Europe under the brand name Forxiga, would no longer be delivered to Germany from Dec. 15.

The two companies could not agree on a price for Forxiga in negotiations with the German association of statutory medical insurers and are pulling the drug even as a round of mediation is continuing.

 

[Anonymous]

Apparently the answer is end it because it is not fixable -- one truth means one company!

 

[Anonymous]

To many reps, but that will all be taken care of next year.

Apparently stupid reps who can't distinguish between to and too..